Immunotherapy in gastrointestinal cancers

Patrick Grierson, Kian Huat Lim, Manik Amin

Research output: Contribution to journalReview article

19 Scopus citations


Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities. This review summarizes the existing and ongoing immunotherapies in the treatment of GI cancers

Original languageEnglish
Pages (from-to)474-484
Number of pages11
JournalJournal of Gastrointestinal Oncology
Issue number3
StatePublished - Jun 1 2017


  • Check point inhibitors
  • Gastrointestinal (GI) cancers
  • Immunotherapies

Fingerprint Dive into the research topics of 'Immunotherapy in gastrointestinal cancers'. Together they form a unique fingerprint.

  • Cite this